Traditionally, MET, a biguanide-derived drug, is used in the treatment of diabetes mellitus type 2 as a modulator of insulin sensitivity by decreasing hepatic gluconeogenesis and lipogenesis. Here, INS is linked to type 2 diabetes mellitus.